Clinical trial
Prospective, Non-interventional, Multi-centre Clinical Study to Assess the Clinical Validity of the Heparin Binding Protein (HBP) Assay for Indicating the Presence, or Outcome, of Severe Sepsis (Including Septic Shock), Over 72 Hours, in Patients With Suspected Infection Following Emergency Department Admission.
NCT01392508 is registered in ClinicalTrials.gov with Axis Shield Diagnostics Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective, Non-interventional, Multi-centre Clinical Study to Assess the Clinical Validity of the Heparin Binding Protein (HBP) Assay for Indicating the Presence, or Outcome, of Severe Sepsis (Including Septic Shock), Over 72 Hours, in Patients With Suspected Infection Following Emergency Department Admission.
- Lead sponsor
- Axis Shield Diagnostics Ltd
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 31, 2011
- Completion date
- September 30, 2015
- Enrollment
- 759 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
sepsis, septic shock, severe sepsis, systemic inflammatory response syndrome (sirs)